Larimar Therapeutics (LRMR) News Today $6.08 -0.30 (-4.70%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Brokerages Set Larimar Therapeutics, Inc. (NASDAQ:LRMR) Target Price at $20.43November 21 at 1:43 AM | americanbankingnews.comLarimar Therapeutics (NASDAQ:LRMR) Given "Outperform" Rating at William BlairWilliam Blair reaffirmed an "outperform" rating on shares of Larimar Therapeutics in a research report on Tuesday.November 19 at 11:45 AM | marketbeat.comPromising Prospects for Larimar Therapeutics: Analyst Upgrades Stock to Buy Amid Positive Drug Developments and Strong Financial OutlookNovember 19 at 7:38 AM | markets.businessinsider.comLarimar Therapeutics presents Phase 1 and 2 dose studies of nomlabofuspNovember 19 at 7:38 AM | markets.businessinsider.comLarimar Therapeutics (NASDAQ:LRMR) Given "Buy" Rating at HC WainwrightHC Wainwright reissued a "buy" rating and set a $15.00 price objective on shares of Larimar Therapeutics in a report on Monday.November 18 at 1:41 PM | marketbeat.comLarimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Rating of "Buy" from AnalystsShares of Larimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) have been given a consensus rating of "Buy" by the ten analysts that are presently covering the company, MarketBeat.com reports. Nine analysts have rated the stock with a buy recommendation and one has assigned a strong buy recoNovember 18 at 3:18 AM | marketbeat.comIs Larimar Therapeutics (LRMR) the Best Multibagger Stock to Buy Heading into 2025?November 16, 2024 | msn.comWhat is HC Wainwright's Forecast for LRMR FY2024 Earnings?Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Research analysts at HC Wainwright upped their FY2024 earnings estimates for Larimar Therapeutics in a note issued to investors on Wednesday, October 30th. HC Wainwright analyst E. White now forecasts that the company will post earnings ofNovember 4, 2024 | marketbeat.comOppenheimer Keeps Their Buy Rating on Larimar Therapeutics (LRMR)November 2, 2024 | markets.businessinsider.comAssenagon Asset Management S.A. Sells 383,554 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR)Assenagon Asset Management S.A. lessened its holdings in shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) by 62.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 226,475 shares of the compaNovember 2, 2024 | marketbeat.comLarimar Therapeutics Reports Third-Quarter 2024 Financial and Operational ProgressOctober 31, 2024 | msn.comCiti opens ‘positive catalyst watch’ on Larimar Therapeutics into dataOctober 31, 2024 | markets.businessinsider.comLarimar Therapeutics Q3 2024 Financial UpdateOctober 31, 2024 | markets.businessinsider.comLarimar Therapeutics (NASDAQ:LRMR) Posts Earnings Results, Beats Estimates By $0.13 EPSLarimar Therapeutics (NASDAQ:LRMR - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.37) by $0.13. During the same quarter last year, the company posted ($0.21) earnings per share.October 31, 2024 | marketbeat.comLarimar Therapeutics (NASDAQ:LRMR) Receives "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $15.00 price target on shares of Larimar Therapeutics in a research report on Thursday.October 31, 2024 | marketbeat.comLarimar Therapeutics (NASDAQ:LRMR) Shares Gap Up - Should You Buy?Larimar Therapeutics (NASDAQ:LRMR) Shares Gap Up - Should You Buy?October 30, 2024 | marketbeat.comLarimar Therapeutics Reports Third Quarter 2024 Operating and Financial ResultsOctober 30, 2024 | globenewswire.comBullish Outlook on Larimar Therapeutics Amid Upcoming OLE Data and Promising Drug DevelopmentsOctober 28, 2024 | markets.businessinsider.comLarimar Therapeutics (NASDAQ:LRMR) Stock Price Up 6.8% - Should You Buy?Larimar Therapeutics (NASDAQ:LRMR) Trading Up 6.8% - Here's What HappenedOctober 24, 2024 | marketbeat.comOppenheimer Initiates Coverage of Larimar Therapeutics (LRMR) with Outperform RecommendationOctober 17, 2024 | msn.comLarimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For StockOctober 16, 2024 | benzinga.comLarimar initiated with bullish view at Oppenheimer on lead drugOctober 16, 2024 | msn.comLarimar Therapeutics (NASDAQ:LRMR) Shares Gap Up - What's Next?Larimar Therapeutics (NASDAQ:LRMR) Shares Gap Up - Time to Buy?October 16, 2024 | marketbeat.comOppenheimer Initiates Coverage on Larimar Therapeutics (NASDAQ:LRMR)Oppenheimer assumed coverage on shares of Larimar Therapeutics in a research note on Wednesday. They issued an "outperform" rating and a $26.00 price objective for the company.October 16, 2024 | marketbeat.comMillennium Management LLC Boosts Holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR)Millennium Management LLC increased its position in Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) by 30.2% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,018,135 shares ofOctober 10, 2024 | marketbeat.comLarimar Therapeutics (NASDAQ:LRMR) Stock, Short Interest ReportOctober 6, 2024 | benzinga.comLarimar Therapeutics (NASDAQ:LRMR) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comWedbush Initiates Coverage of Larimar Therapeutics (LRMR) with Outperform RecommendationOctober 5, 2024 | msn.comResearch Analysts Offer Predictions for Larimar Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:LRMR)Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Equities research analysts at HC Wainwright issued their Q3 2024 earnings per share estimates for shares of Larimar Therapeutics in a report issued on Wednesday, October 2nd. HC Wainwright analyst E. White expects that the company will earnOctober 4, 2024 | marketbeat.comLarimar started at outperform by Wedbush on FA drug candidateOctober 3, 2024 | msn.comPoint72 Asset Management L.P. Raises Stock Holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR)Point72 Asset Management L.P. boosted its stake in Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) by 37.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 603,581 shares of the compaOctober 3, 2024 | marketbeat.comAnalysts Conflicted on These Healthcare Names: Accolade (ACCD) and Larimar Therapeutics (LRMR)October 3, 2024 | markets.businessinsider.comHC Wainwright & Co. Initiates Coverage of Larimar Therapeutics (LRMR) with Buy RecommendationOctober 3, 2024 | msn.comLarimar Therapeutics (NASDAQ:LRMR) Now Covered by HC WainwrightHC Wainwright initiated coverage on shares of Larimar Therapeutics in a report on Wednesday. They set a "buy" rating and a $15.00 price target for the company.October 2, 2024 | marketbeat.comDriehaus Capital Management LLC Has $9.53 Million Stake in Larimar Therapeutics, Inc. (NASDAQ:LRMR)Driehaus Capital Management LLC boosted its holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) by 20.8% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,314,106 shares of the company's stock after acquiringSeptember 30, 2024 | marketbeat.comLarimar Therapeutics, Inc. (NASDAQ:LRMR) Given Average Rating of "Buy" by BrokeragesShares of Larimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) have received a consensus recommendation of "Buy" from the seven analysts that are presently covering the company, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy rating and one has given a strSeptember 29, 2024 | marketbeat.comLarimar Therapeutics, Inc. (NASDAQ:LRMR) Stock Position Decreased by Blue Owl Capital Holdings LPBlue Owl Capital Holdings LP lowered its stake in Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) by 3.4% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,859,468 shares of the company's stock after selling 135,000 shSeptember 28, 2024 | marketbeat.comLarimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia ResearchSeptember 19, 2024 | globenewswire.comJones Trading Initiates Coverage of Larimar Therapeutics (LRMR) with Buy RecommendationSeptember 13, 2024 | nasdaq.comJones Research starts Larimar at buy, cites lead asset nomlabofuspSeptember 12, 2024 | msn.comLarimar Therapeutics (NASDAQ:LRMR) Shares Up 6.1%Larimar Therapeutics (NASDAQ:LRMR) Shares Up 6.1%September 10, 2024 | marketbeat.comLarimar Therapeutics (NASDAQ:LRMR) Trading Down 4.7%Larimar Therapeutics (NASDAQ:LRMR) Trading Down 4.7%September 6, 2024 | marketbeat.comLarimar Therapeutics (NASDAQ:LRMR) Sees Large Volume IncreaseLarimar Therapeutics (NASDAQ:LRMR) Sees Strong Trading VolumeSeptember 5, 2024 | marketbeat.comBuy Rating Affirmed for Larimar Therapeutics: High Potential for U.S. Approval and Market Share in Friedreich’s Ataxia TreatmentSeptember 5, 2024 | markets.businessinsider.comBaird Initiates Coverage of Larimar Therapeutics (LRMR) with Outperform RecommendationSeptember 5, 2024 | msn.comBaird R W Upgrades Larimar Therapeutics (NASDAQ:LRMR) to Strong-BuyBaird R W raised Larimar Therapeutics to a "strong-buy" rating in a research report on Wednesday.September 5, 2024 | marketbeat.comLarimar Therapeutics (NASDAQ:LRMR) Earns Outperform Rating from Analysts at Robert W. BairdRobert W. Baird started coverage on shares of Larimar Therapeutics in a report on Wednesday. They set an "outperform" rating and a $16.00 price objective on the stock.September 4, 2024 | marketbeat.comLarimar Therapeutics Engages with Investors at Key ConferencesAugust 29, 2024 | msn.comLarimar Therapeutics to Participate in Upcoming Investor ConferencesAugust 27, 2024 | finance.yahoo.comVanguard Group Inc. Buys 912,458 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR)Vanguard Group Inc. boosted its position in Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) by 62.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,367,701 shares of the company's stock aftAugust 12, 2024 | marketbeat.com Get Larimar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LRMR and its competitors with MarketBeat's FREE daily newsletter. Email Address 📉 Warning: Market Crash Predicted - Secure Your Savings (Ad)The last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%. Take these 4 steps to protect your retirement here >>> LRMR Media Mentions By Week LRMR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LRMR News Sentiment▼0.650.45▲Average Medical News Sentiment LRMR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LRMR Articles This Week▼93▲LRMR Articles Average Week Get Larimar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LRMR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Kamada News Altimmune News Fulcrum Therapeutics News Arbutus Biopharma News BeyondSpring News Hookipa Pharma News Unity Biotechnology News Nurix Therapeutics News Arvinas News Kiniksa Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LRMR) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Larimar Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Larimar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
